---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-002431"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-07-21T23:59:59+00:00"
generated_at: "2026-05-18T05:21:58.232328+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Silexion receives Nasdaq bid price deficiency notice; reverse split set for July 29

## Summary
- On July 18, 2025, Nasdaq notified Silexion that its ordinary shares' closing bid price was below $1.00 for 30 consecutive days.
- Bid price deficiency will be considered by Nasdaq hearings panel in continued listing decision.
- Shareholder-approved 1-for-15 reverse split effective after market close July 28; trading begins split-adjusted July 29.
- Company must also meet $2.5M minimum shareholders' equity by September 19, 2025 to maintain listing.
- Current trading of shares (SLXN) and warrants (SLXNW) unaffected at this time.

## SEC filing metadata
- accession: 0001178913-25-002431
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-07-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002431/0001178913-25-002431-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002431/zk2533462.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-002431
- JSON: https://secwatch.observer/filing/0001178913-25-002431.json
- Plain text: https://secwatch.observer/filing/0001178913-25-002431.txt

## Key facts
- Listing & Compliance Notices
  Silexion Therapeutics Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: July 18, 2025, Silexion Therapeutics Corp (the “ Company ” or “ Silexion ”) received a letter from the Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the 30 consecutive business days preceding the letter, the closing bid price of the Company’s ordinary shares, par value $0.0009 per share (“ ordinary share s”), was below the minimum $1.00 per share required for continued listing on The Nasdaq Stock Market LLC under Nasdaq Listing Rule 5550(a)(2) (the “ bid price deficiency ”). The Staff indicated in the letter that
  evidence_url: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002431/0001178913-25-002431-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.